Opinions
Robert McWhirter
VentriPoint Diagnostics
VPT-X
BUY
Apr 12, 2021
They take 2D images of the heart and convert to 3D. It's an alternative to an MRI, which is hard to access now. They may be wildly successful in China where they are testing their procedure. If China grants approval, then the opportunity here would be breathtaking.
$0.520
Stock price when the opinion was issued
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
BUY
Takes a 2D ultrasound image and converts it to a 3D image that can be observed by surgeons. GE has a large number of ultrasound machines in the marketplace. Has asked them to adapt VentriPoint's system to their machines. China is also interested in adding their tech to their hospitals.
Healthcare
RISKY
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The company develops and commercializes diagnostic tools to monitor heart disease. Minimal to no revenues so still very speculative. Largely in the development phase. They signed new contracts with GE Healthcare Corp and new patents are being filed. Unlock Premium - Try 5i Free
Healthcare
Advertising